CellWell record HH-521847
Specialty grand challenge editorial innovative approaches for pharmacoepidemiologic research in pregnancy: Shifting the paradigm of Thalidomide’s impact on pregnant women
Eva Gerbier; Alice Panchaud
Frontiers in Drug Safety and Regulation · 2023
In plain language
This editorial reports that nearly 98% of drugs approved by the FDA from 2000 to 2010 carried an undetermined teratogenic risk, a gap linked to long-standing exclusion of pregnant women from trials.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-521847
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.